SQI Diagnostics

183 articles about SQI Diagnostics

• SQI Diagnostics Announces Receipt of Intention to Enforce Security from Pivot Financial and Anticipated Voluntary Bankruptcy Filing

  6/16/2023

  SQI Diagnostics Inc. announced that the Company's board of directors has received a notice of intention to enforce security issued by its senior secured creditor, Pivot Financial I Limited Partnership, under Section 244 of the Bankruptcy and Insolvency Act.

• SQI Diagnostics Reports Internal Restructuring

  6/6/2023

  SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests announced that the Company's board of directors has issued layoff notices to each of Andrew Morris, the Company's Chief Executive, and Eric Brouwer, the Company's Chief Scientific Officer, in an effort to further reduce the Company's expenses.

• SQI Diagnostics Reports Second Quarter 2023 Results

  5/30/2023

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests today reported its financial and operational results for the second quarter ended March 31, 2022. 

• SQI to Focus on Development of Point of Care Products In Respiratory Health

  3/28/2023

  SQI Diagnostics Inc., a leader in the science of lung health, announced that it is moving to strategically focus on what is now its core business: creating precision Point of Care products in respiratory health.

• SQI DIAGNOSTICS ANNOUNCES PROPOSED INSIDER SALES AND WARRANT EXERCISES TO FUND COMPANY

  3/24/2023

  SQI Diagnostics Inc. announces that certain insiders of the Company, who are also control persons of the Company and collectively own, or exercise control or direction over, an aggregate of 75% of the issued and outstanding common shares.

• SQI Diagnostics Announces New Capital Markets Consulting Agreement

  3/13/2023

  SQI Diagnostics Inc. today announces that it has entered into a new consulting agreement with Looking Glass Capital Consultants.

• Four Diagnostic Products in the Pipeline at SQI

  3/3/2023

  SQI Diagnostics Inc. announced it is developing three diagnostic products based on University Health Network innovations and is exploring an initiative with Owlstone Medical and UHN on a fourth diagnostic product.

• SQI Diagnostics Reports First Quarter 2023 Results

  3/1/2023

  SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the first quarter ended December 31, 2022.

• SQI Diagnostics Reports Fourth Quarter and Fiscal 2022 Results

  1/31/2023

  SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2022.

• SQI installs two RALI-DX systems in Toronto hospitals to fight the growing respiratory health crisis in Emergency Departments

  1/18/2023

  SQI Diagnostics Inc. announced that its Rapid Acute Lung Injury Diagnostic IL-6 Severity Triage Test has been installed in two University Health Network hospitals in Toronto to use as a clinical aid to help assess respiratory patients in the Emergency Department and as part of a study to help fight the growing respiratory health crisis in EDs.

• SQI Diagnostics Secures Up To $2 Million in FedDev Ontario Funding

  11/10/2022

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF) today announced that it has entered into a funding agreement (the "Contribution Agreement") with the Federal Economic Development Agency for Southern Ontario ("FedDev Ontario") to support the Company's manufacturing scale-up and commercialization of its pipeline of products in development, including the Company's recently approved RALI-DX IL-6 test. 

• SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

  10/17/2022

  SQI Diagnostics Inc. today announced it has received Health Canada Interim Order authorization for its Rapid Acute Lung Injury Diagnostic (RALI-Dx™) IL-6 Severity Triage Test.

• SQI Diagnostics Announces Grant of Stock Options - Aug 31, 2022

  8/31/2022

  SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests announced that effective August 26, 2022, it has granted an aggregate of 2,877,500 stock options to certain employees and officers of the Company under the Company's amended and restated stock option plan.

• SQI Diagnostics Reports Third Quarter 2022 Results

  8/29/2022

  SQI Diagnostics Inc. today reported its financial and operational results for the third quarter for fiscal year ending September 30, 2022.

• SQI Diagnostics Reports Second Quarter 2022 Results

  5/26/2022

  SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported its financial and operational results for the first quarter for fiscal year ending September 30, 2022.

• SQI Diagnostics Inc. to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT

  3/25/2022

  SQI Diagnostics Inc. announced today that Company CEO Andrew Morris has been invited to present at the 2022 Virtual Growth Conference.

• New York State Approves SQI Diagnostics' EXACT COVID-19 Antibody Assay

  3/3/2022

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), leaders in the science of lung health, announced today that New York State Department of Health (NYSDOH) has given conditional approval to its diagnostic testing partner, KSL Diagnostics, Inc. in Buffalo NY, for the EXACT COVID-19 Antibody Test.

• SQI Diagnostics Reports First Quarter 2022 Results

  3/1/2022

  SQI Diagnostics Inc., a leader in the science of lung health that develops and manufactures respiratory health and precision medicine tests reported their financial and operational results for the first quarter for fiscal year ending September 30, 2022.

• SQI Diagnostics Reports Fourth Quarter and Fiscal 2021 Results

  1/26/2022

  SQI Diagnostics Inc. ('SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2021.

• SQI Diagnostics Inc Signs MOU with UK-Based Owlstone Medical

  1/24/2022

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), is pleased to announce a Memorandum of Understanding ("MOU") between SQI and Owlstone Medical to work together on the discovery, development and commercialization of breath-based biomarkers relating to invasive aspergillus lung infection and lung transplant rejection.